ClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials
- 20 September 2016
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 165 (6) , 421-430
Abstract
Pharmaceutical companies and other trial sponsors must submit certain trial results to ClinicalTrials.gov. The validity of these results is unclear. To validate results posted on ClinicalTrials.gov against publicly available U.S. Food and Drug Administration (FDA) reviews on Drugs@FDA. ClinicalTrials.gov (registry and results database) and Drugs@FDA (medical and statistical reviews). 100 parallel-group, randomized trials for new drug approvals (January 2013 to July 2014) with results posted on ClinicalTrials.gov (15 March 2015). 2 assessors extracted, and another verified, the trial design, primary and secondary outcomes, adverse events, and deaths. Most trials were phase 3 (90%), double-blind (92%), and placebo-controlled (73%) and involved 32 drugs from 24 companies. Of 137 primary outcomes identified from ClinicalTrials.gov, 134 (98%) had corresponding data at Drugs@FDA, 130 (95%) had concordant definitions, and 107 (78%) had concordant results. Most differences were nominal (that is, relative difference <10%). Primary outcome results in 14 trials could not be validated. Of 1927 secondary outcomes from ClinicalTrials.gov, Drugs@FDA mentioned 1061 (55%) and included results data for 367 (19%). Of 96 trials with 1 or more serious adverse events in either source, 14 could be compared and 7 had discordant numbers of persons experiencing the adverse events. Of 62 trials with 1 or more deaths in either source, 25 could be compared and 17 were discordant. Unknown generalizability to uncontrolled or crossover trial results. Primary outcome definitions and results were largely concordant between ClinicalTrials.gov and Drugs@FDA. Half the secondary outcomes, as well as serious events and deaths, could not be validated because Drugs@FDA includes only “key outcomes” for regulatory decision making and frequently includes only adverse event results aggregated across multiple trials. National Library of Medicine.Keywords
This publication has 21 references indexed in Scilit:
- Haphazard reporting of deaths in clinical trials: a review of cases of ClinicalTrials.gov records and matched publications–a cross-sectional studyBMJ Open, 2013
- The ClinicalTrials.gov Results Database — Update and Key IssuesNew England Journal of Medicine, 2011
- Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label UseNew England Journal of Medicine, 2009
- Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and PresentationPLOS Medicine, 2008
- Publication of Clinical Trials Supporting Successful New Drug Applications: A Literature AnalysisPLOS Medicine, 2008
- Selective Publication of Antidepressant Trials and Its Influence on Apparent EfficacyNew England Journal of Medicine, 2008
- A Taxpayer-Funded Clinical Trials Registry and Results DatabasePLOS Medicine, 2004
- Empirical Evidence for Selective Reporting of Outcomes in Randomized TrialsJAMA, 2004
- Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?BMJ, 2002
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000